ライフサイエンスコーパス: the index date

1 The date of diagnosis was defined as the index date.

2 SSE rates were computed after the index date.

3 use between survivors and controls declined each year after the index date.

4 , and 5 or more years (RR, 1.29; 95% CI, 1.22 to 1.36) from the index date.

5 ore was assessed using electronic health record data before the index date.

6 urs, and >23.5 hours) was assessed over the 6 months before the index date.

7 er survivors was less than that of controls each year after the index date.

8 (i.e., index date), and years of history in the CPRD before the index date.

9 within 30 days (current use) and other time windows before the index date.

10 continued for 24 months minimum and 10 years maximum after the index date.

11 m 42.4% among uninfected men to 56.7% among infected men on the index date.

12 testing or any follow-up testing at any anatomic site after the index date.

13 prescription coverage for at least 1 year before and after the index date.

14 use was defined as prescription fillings 6 months prior to the index date.

15 l 562,300 study patients, 296,975 (52.81%) had HTN prior to the index date, 63,528 (56.49%) among cases and 233,447 (51.9

16 Within 1 year before the index date, 68% of cases and 52% of controls used a PPI,

17 tes (VSD site, age at last dose, sex, and calendar month of the index date), a statistically significant protective assoc

18 We identified CRC from the Ontario Cancer Registry between the index date and December 31, 2014.

19 ty of pharyngeal or urine specimens tested for GC and CT on the index date, and the frequency and positivity of repeat re

20 In sensitivity analyses, we shifted the index date backwards by 2 years, and we restricted our an

21 e was the source of opioid prescriptions within 6 months of the index date, categorized as VA only, Part D only, or VA an

22 two controls (n = 4,604) by age, sex, and race/ethnicity on the index date corresponding with the case diagnosis date.

23 Exclusion of antiepileptic drugs prescribed before the index date did not meaningfully alter the findings, nor d

24 nsity score matching was used at baseline (12 months before the index date: first OCS use).

25 The date of diagnosis was the index date for case patients and their controls.

26 The index date for each patient was the later of the date HIV

27 ly because of cancers arising within 1 year before or after the index date for PD, but risk of smoking-related cancers wa

28 first recording of a diagnosis of Parkinson's disease after the index date, identified from clinical records.

29 ontrol study and defined exposure to antiepileptic drugs at the index date (ie, time of suicide).

30 epilepsy before the case patient's epilepsy was diagnosed (the index date), matched by year of birth, sex, and general p

31 ncy in the period from 5 years before, until 5 years after, the index date of the diagnosis of breast cancer.

32 date (HR = 1.53, 95% CI: 1.23, 1.91) and from 1 year after the index date onward (HR = 1.46, 95% CI: 1.01, 2.10).

33 Current FQ exposure implied an active prescription at the index date or 30 days prior to the event date.

34 PPI usage up to 90 days before the index date remained statistically significant.

35 ded HSCT, the rate remained elevated more than 5 years from the index date (RR, 1.29; 95% CI, 1.23 to 1.35).

36 d for competing risks demonstrated that at 1-year following the index date, superficial and deep/organ space SSIs were si

37 In the first year after the index date (survivor's diagnosis date), chronic use among

38 riteria were missing key data, death sooner than 24 h after the index date, therapy with an active antibiotic for at leas

39 e prescriptions were counted from 1995 until 2 years before the index date, there was a slightly higher odds ratio of dem

40 r whether the patients had prior severe exacerbation before the index date, those receiving angiotensin-converting enzyme

41 conducted a systematic search for studies published between the index date until July 2013 reporting maternal lipid level

42 The mean +/- SD age for NAION cases at the index date was 64.0+/-9.2 years vs. 58.4+/-9.4 years for

43 The mean +/- standard deviation age at the index date was 69.0 +/- 1.5 years for all 3 groups.

44 Among 16 169 matched pairs, average IOP after the index date was lower in the surgical than nonsurgical gro

45 The index date was the date of first nAMD diagnosis in cases.

46 The index date was the first fill for sacubitril/valsartan an

47 users of bisphosphonates in the 1, 2, and 3 years prior to the index date were 1.24 (1.12-1.38), 1.38 (1.22-1.56), and 1

48 When traumas in the 5 years prior to the index date were excluded, there was a borderline associat

49 tamine 2-receptor antagonists (H2RA) during the year before the index date were identified.

50 fects of weight loss (achieved in the first 18 months after the index date) were studied to identify cut-offs for the min